317 related articles for article (PubMed ID: 23556424)
1. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
Verma S; Kroeker KI; Fedorak RN
BMC Gastroenterol; 2013 Apr; 13():59. PubMed ID: 23556424
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for recurrent orbital myositis in Crohn's disease: report of a case with a 3-year follow-up.
Hernández-Garfella ML; Gracia-García A; Cervera-Taulet E; García-Villanueva C; Montero-Hernández J
J Crohns Colitis; 2011 Jun; 5(3):265-6. PubMed ID: 21575896
[No Abstract] [Full Text] [Related]
3. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
5. Orbital myositis in a patient with Crohn's disease: A case report of two episodes.
Oliver-Gutierrez D; Garrido-Marin M; Segura-Duch G; Alonso T; Ros-Sanchez E; Oliveres J
J Fr Ophtalmol; 2024 Apr; 47(4):104048. PubMed ID: 38238142
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of infliximab after adalimumab failure in Crohn's disease.
Chaparro M; Andreu M; Barreiro-de Acosta M; García-Planella E; Ricart E; Domènech E; Esteve M; Merino O; Nos P; Peñalva M; Gisbert JP
World J Gastroenterol; 2012 Oct; 18(37):5219-24. PubMed ID: 23066316
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
Da W; Zhu J; Wang L; Lu Y
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
[TBL] [Abstract][Full Text] [Related]
9. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
11. Recurrent orbital myositis as an extra-intestinal manifestation of Crohn's disease.
Pimentel R; Lago P; Pedroto I
J Crohns Colitis; 2012 Oct; 6(9):958-9. PubMed ID: 22704659
[No Abstract] [Full Text] [Related]
12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
13. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
14. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
[TBL] [Abstract][Full Text] [Related]
16. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
[TBL] [Abstract][Full Text] [Related]
17. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
18. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
19. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]